Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Antisense oligonucleotides for the knock-down of axonal regeneration inhibitors following spinal cord injury

FY 2017-18

Summary
Spinal cord injury (SCI) can result in a plethora of symptoms including bladder and sexual dysfunction, as well as pain and persistent paralysis. This makes spinal cord injury (SCI) emotionally, physically and financially devastating for the individual, their families and the health care system. Chronic paralysis is a result of spinal cord nerve fibres, referred to as axons, failing to regrow after they have been injured and disconnected from the brain. This regenerative failure is due in part to the environment of the spinal cord injury site which itself inhibits regrowth, as well as a loss of growth propensity of mammalian nerve cells. Nerve regeneration has in fact been observed in miceafter genetic deletion of molecules that normally inhibit nerve regrowth after injury, including PTEN, SOCS3 and ROCK2, resulting in promising targets for spinal cord injury therapeutics. However, genetic deletion (knock-out) techniques are not applicable to humans, so new, clinically feasible approaches must be used. The overall objective of this experiment is to promote nerve regrowth using antisense oligonucleotides (ASOs), which block the production of inhibitory molecules that prevent regeneration following SCI. This project is inspired by the successes of ASO technology for several rare diseases in humans, rendering the results of this experiment translatable from laboratory to hospital. If successful, this project may provide a new means of tackling the regeneration failure and disability that follows human SCI.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386569
Name
Hudak Katelyn
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Antisense oligonucleotides for the knock-down of axonal regeneration inhibitors following spinal cord injury
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antisense Oligonucleotides; Axonal Regeneration Inhibitors; Crym-Gfp; Regeneration; Spinal Cord Injury; Tissue Clearing
Abstract
Spinal cord injury (SCI) can result in a plethora of symptoms including bladder and sexual dysfunction, as well as pain and persistent paralysis. This makes spinal cord injury (SCI) emotionally, physically and financially devastating for the individual, their families and the health care system. Chronic paralysis is a result of spinal cord nerve fibres, referred to as axons, failing to regrow after they have been injured and disconnected from the brain. This regenerative failure is due in part to the environment of the spinal cord injury site which itself inhibits regrowth, as well as a loss of growth propensity of mammalian nerve cells. Nerve regeneration has in fact been observed in miceafter genetic deletion of molecules that normally inhibit nerve regrowth after injury, including PTEN, SOCS3 and ROCK2, resulting in promising targets for spinal cord injury therapeutics. However, genetic deletion (knock-out) techniques are not applicable to humans, so new, clinically feasible approaches must be used. The overall objective of this experiment is to promote nerve regrowth using antisense oligonucleotides (ASOs), which block the production of inhibitory molecules that prevent regeneration following SCI. This project is inspired by the successes of ASO technology for several rare diseases in humans, rendering the results of this experiment translatable from laboratory to hospital. If successful, this project may provide a new means of tackling the regeneration failure and disability that follows human SCI.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hudak, Katelyn
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~